Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Emerging therapies for the management of Richter transformation

Practical management of chronic lymphocytic leukemia with acalabrutinib

Patient Story: Adam Carty

Patients with Blood Cancer & COVID-19

BCRWA @ The 63rd ASH Annual Meeting & Exposition 2021

Dr. Katharine Lewis to present Oral Abstract at ASH Annual Meeting 2021

Therapeutic Options for Relapsed/Refractory Mantle Cell Lymphoma

Professor Cheah ranked in the top 0.1% of lymphoma scholars globally

Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies